Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213717 | 1.00 | FAAH (0.41) | FAAHALDH1A1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL5214115 | 0.81 | EPHX1 (0.57) | FAAHALDH1A1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL5214126 | 0.81 | EPHX1 (0.57) | FAAHALDH1A1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL5218361 | 0.80 | PTGS1 (0.56) | ALDH1A1HTTSMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL5248185 | 0.77 | CXCR2 (0.63) | FAAHALDH1A1HTTSMN1; SMN2CA12 | |
| SCHEMBL15285417 | 0.77 | FAAH (0.64) | FAAHEPHX1CA12CA1CA2 | |
| SCHEMBL2237283 | 0.77 | FAAH (0.64) | FAAHEPHX1CA12CA1CA2 | |
| SCHEMBL3886291 | 0.73 | ALOX5 (0.44) | FAAHSMN1; SMN2EPHX1CA2ALOX5 | |
| SCHEMBL5219685 | 0.73 | APP (0.43) | FAAHALDH1A1HTTSMN1; SMN2CXCR1 | |
| SCHEMBL5217986 | 0.70 | TRPV1 (0.43) | ALDH1A1HTTSMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | FAAH 330/4885ALDH1A1 391/4885HTT 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.